Menu
Back to Journals » Lung Cancer: Targets and Therapy » Volume 9
Lung Cancer: Targets and Therapy
ISSN: 1179-2728
- View all (178)
- Volume 15, 2024 (6)
- Volume 14, 2023 (12)
- Volume 13, 2022 (8)
- Volume 12, 2021 (14)
- Volume 11, 2020 (11)
- Volume 10, 2019 (16)
- Volume 9, 2018 (14)
- Volume 8, 2017 (25)
- Volume 7, 2016 (17)
- Volume 6, 2015 (9)
- Volume 5, 2014 (10)
- Volume 4, 2013 (9)
- Volume 3, 2012 (9)
- Volume 2, 2011 (6)
- Volume 1, 2010 (12)
Archive: Volume 9, 2018
Dramatic response to alectinib in a lung cancer patient with a novel VKORC1L1-ALK fusion and an acquired ALK T1151K mutation
Zhu VW, Schrock AB, Bosemani T, Benn BS, Ali SM, Ou SI
Lung Cancer: Targets and Therapy 2018, 9:111-116
Published Date: 8 November 2018
Clinical outcomes following advanced respiratory motion management (respiratory gating or dynamic tumor tracking) with stereotactic body radiation therapy for stage I non-small-cell lung cancer
Aridgides P, Nsouli T, Chaudhari R, Kincaid R, Rosenbaum PF, Tanny S, Mix M, Bogart J
Lung Cancer: Targets and Therapy 2018, 9:103-110
Published Date: 5 November 2018
Silicosis and lung cancer: current perspectives
Sato T, Shimosato T, Klinman DM
Lung Cancer: Targets and Therapy 2018, 9:91-101
Published Date: 26 October 2018
Non-small cell to small cell lung cancer on PD-1 inhibitors: two cases on potential histologic transformation
Abdallah N, Nagasaka M, Abdulfatah E, Shi D, Wozniak AJ, Sukari A
Lung Cancer: Targets and Therapy 2018, 9:85-90
Published Date: 25 October 2018
Amifostine- and chemoradiotherapy-related esophagitis in small cell lung cancer: a single institutional series and literature update
Pollock AE, Shinn L, Anderson R, Butler S, Pollock J
Lung Cancer: Targets and Therapy 2018, 9:79-84
Published Date: 10 September 2018
Hypersensitivity in ALK-positive lung cancers exposed to ALK inhibitors: a case of successful switch to an alternative ALK inhibitor and systematic review of the literature
Deng L, Sharma J, Ravera E, Halmos B, Cheng H
Lung Cancer: Targets and Therapy 2018, 9:73-77
Published Date: 6 September 2018
1-, 3-, and 5-year survival among early-stage lung cancer patients treated with lobectomy vs SBRT
Albano D, Bilfinger T, Nemesure B
Lung Cancer: Targets and Therapy 2018, 9:65-71
Published Date: 24 August 2018
Comprehensive review of fetal adenocarcinoma of the lung
Ricaurte LM, Arrieta O, Zatarain-Barrón ZL, Cardona AF
Lung Cancer: Targets and Therapy 2018, 9:57-63
Published Date: 23 August 2018
Prophylactic cranial irradiation in small-cell lung cancer: update on patient selection, efficacy and outcomes
Manapov F, Käsmann L, Roengvoraphoj O, Dantes M, Schmidt-Hegemann NS, Belka C, Eze C
Lung Cancer: Targets and Therapy 2018, 9:49-55
Published Date: 16 August 2018
Response to rapamycin analogs but not PD-1 inhibitors in PTEN-mutated metastatic non-small-cell lung cancer with high tumor mutational burden
Parikh AR, Ali SM, Schrock AB, Albacker LA, Miller VA, Stephens PJ, Crilley P, Markman M
Lung Cancer: Targets and Therapy 2018, 9:45-47
Published Date: 18 May 2018
Role and inhibition of GLI1 protein in cancer
Mastrangelo E, Milani M
Lung Cancer: Targets and Therapy 2018, 9:35-43
Published Date: 27 March 2018
Uncommon EGFR mutations in cytological specimens of 1,874 newly diagnosed Indonesian lung cancer patients
Syahruddin E, Wulandari L, Sri Muktiati N, Rima A, Soeroso N, Ermayanti S, Levi M, Hidajat H, Widjajahakim G, Utomo ARH
Lung Cancer: Targets and Therapy 2018, 9:25-34
Published Date: 23 March 2018
Stereotactic body radiation therapy (SBRT) in the management of non-small-cell lung cancer: Clinical impact and patient perspectives
Donovan EK, Swaminath A
Lung Cancer: Targets and Therapy 2018, 9:13-23
Published Date: 16 March 2018
Validation of liquid biopsy: plasma cell-free DNA testing in clinical management of advanced non-small cell lung cancer
Veldore VH, Choughule A, Routhu T, Mandloi N, Noronha V, Joshi A, Dutt A, Gupta R, Vedam R, Prabhash K
Lung Cancer: Targets and Therapy 2018, 9:1-11
Published Date: 3 January 2018